CN106377677A - 一种用于治疗风湿病的药物及其制备方法 - Google Patents
一种用于治疗风湿病的药物及其制备方法 Download PDFInfo
- Publication number
- CN106377677A CN106377677A CN201611107181.3A CN201611107181A CN106377677A CN 106377677 A CN106377677 A CN 106377677A CN 201611107181 A CN201611107181 A CN 201611107181A CN 106377677 A CN106377677 A CN 106377677A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- herba dendrobii
- liquid
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 34
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 24
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims abstract description 15
- 229960004025 sodium salicylate Drugs 0.000 claims abstract description 15
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004472 Lysine Substances 0.000 claims abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 13
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 13
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000681 leflunomide Drugs 0.000 claims abstract description 13
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- 229960001948 caffeine Drugs 0.000 claims abstract description 12
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000011259 mixed solution Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 14
- 239000004100 Oxytetracycline Substances 0.000 claims description 12
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 12
- 229960000625 oxytetracycline Drugs 0.000 claims description 12
- 235000019366 oxytetracycline Nutrition 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 12
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 claims description 11
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 claims description 11
- 150000001904 cucurbitacins Chemical class 0.000 claims description 11
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 229960003646 lysine Drugs 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- UZEAHFLEZWXHCE-UHFFFAOYSA-N 3-iodo-2-methylaniline Chemical compound CC1=C(N)C=CC=C1I UZEAHFLEZWXHCE-UHFFFAOYSA-N 0.000 abstract 2
- 240000004638 Dendrobium nobile Species 0.000 abstract 2
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940063650 terramycin Drugs 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 240000009087 Crescentia cujete Species 0.000 description 3
- 235000005983 Crescentia cujete Nutrition 0.000 description 3
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于治疗风湿病的药物，由以下原料按照重量份组成：辅料2‑5份、石斛液3‑7份、水杨酸钠1‑2份、来氟米特0.2‑1.5份、谷维素2‑4份、维生素E0.2‑1份、赖氨酸2‑4份、咖啡因1‑4份、葫芦素4‑9份、阿司匹林0.5‑2.5份、土霉素0.4‑2份、甘油3‑6份和生理盐水10‑18份。本发明还公布了该药物的制备方法。本发明原料来源广泛，制备工艺简单，适用于大规模的工业化生产；本发明中石斛液、葫芦素、水杨酸钠等组分起协同作用，配方合理，使用方便，治疗时间短，可以彻底治愈风湿病，不易复发并且没有毒副作用，使用效果好。
Description
技术领域
本发明涉及医药制备领域，具体是一种用于治疗风湿病的药物。
背景技术
风湿病是一种常见的疾病，风湿病是一组侵犯关节、骨骼、肌肉、血管及有关软组织或结缔组织为主的疾病，其中多数为自身免疫性疾病。风湿病的发病多较隐蔽而缓慢，病程较长，且大多具有遗传倾向。风湿病是一类侵犯多种组织多系统和内脏器官的自身免疫性疾病，是程度不同的免疫性炎症反应，可致成各种组织和器官损伤，严重影响其正常功能，甚至造成致命性损害。此外，大多数风湿病都有关节症状。治疗风湿性疾病的药物包括非甾类抗炎药、肾上腺皮质激素、慢作用抗风湿药物和云克等药物。但是现有的药物只能缓解风湿病的症状，并不能根治，治疗时间长，花费金钱多，长期服用具有一定的药物依赖性和副作用，这就为风湿病患者带来了困扰。
发明内容
本发明的目的在于提供一种用于治疗风湿病的药物，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种用于治疗风湿病的药物，由以下原料按照重量份组成：辅料2-5份、石斛液3-7份、水杨酸钠1-2份、来氟米特0.2-1.5份、谷维素2-4份、维生素E0.2-1份、赖氨酸2-4份、咖啡因1-4份、葫芦素4-9份、阿司匹林0.5-2.5份、土霉素0.4-2份、甘油3-6份和生理盐水10-18份。
作为本发明进一步的方案：石斛汁液采用石斛煎煮2-4次，每次1-2小时，合并煎煮后的液体并且去除残渣得到。
作为本发明进一步的方案：辅料采用淀粉、糊精、聚维酮、硬脂酸钠、植物油、明胶、羧甲基淀粉钠、液体石蜡和虫胶的一种或者几种的混合物。
所述用于治疗风湿病的药物的制备方法，具体步骤如下：
步骤一，将水杨酸钠、来氟米特和阿司匹林混合在一起，研磨成粉末并且过30-50目筛子，得到第一混合物，备用；
步骤二，将谷维素、维生素E、赖氨酸、咖啡因、葫芦素和土霉素放入生理盐水中，搅拌机在常温下以120-180rpm的转速搅拌15-25分钟，即可得到第一混合溶液；
步骤三，将第一混合物加入第一混合溶液中并且进行搅拌，边搅拌边加入石斛液和甘油，完全加入完毕后搅拌机在30-45摄氏度下以240-360rpm的转速搅拌30-50分钟，得到第二混合溶液，再将第二混合溶液进行浓缩和干燥，得到干浸膏，将干浸膏粉碎成粉末并且与辅料充分混合均匀，制成片剂、丸剂或者胶囊。
与现有技术相比，本发明的有益效果是：本发明原料来源广泛，制备工艺简单，适用于大规模的工业化生产；本发明中石斛液、葫芦素、水杨酸钠等组分起协同作用，配方合理，使用方便，治疗时间短，可以彻底治愈风湿病，不易复发并且没有毒副作用，使用效果好。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种用于治疗风湿病的药物，由以下原料按照重量份组成：辅料2份、石斛液3份、水杨酸钠1份、来氟米特0.2份、谷维素2份、维生素E0.2份、赖氨酸2份、咖啡因1份、葫芦素4份、阿司匹林0.5份、土霉素0.4份、甘油3份和生理盐水10份。石斛汁液采用石斛煎煮3次，每次1.5小时，合并3次煎煮后的液体并且去除残渣得到。
所述用于治疗风湿病的药物的制备方法，具体步骤如下：
步骤一，将水杨酸钠、来氟米特和阿司匹林混合在一起，研磨成粉末并且过30目筛子，得到第一混合物，备用；
步骤二，将谷维素、维生素E、赖氨酸、咖啡因、葫芦素和土霉素放入生理盐水中，搅拌机在常温下以120rpm的转速搅拌18分钟，即可得到第一混合溶液；
步骤三，将第一混合物加入第一混合溶液中并且进行搅拌，边搅拌边加入石斛液和甘油，完全加入完毕后搅拌机在30摄氏度下以270rpm的转速搅拌30分钟，得到第二混合溶液，再将第二混合溶液进行浓缩和干燥，得到干浸膏，将干浸膏粉碎成粉末并且与辅料充分混合均匀，制成片剂、丸剂或者胶囊。
实施例2
一种用于治疗风湿病的药物，由以下原料按照重量份组成：辅料3份、石斛液5份、水杨酸钠1.4份、来氟米特0.8份、谷维素3份、维生素E0.9份、赖氨酸2.6份、咖啡因2.5份、葫芦素6份、阿司匹林1.5份、土霉素1份、甘油4.5份和生理盐水12份。辅料采用淀粉、糊精、明胶、羧甲基淀粉钠、液体石蜡和虫胶的混合物。
所述用于治疗风湿病的药物的制备方法，具体步骤如下：
步骤一，将水杨酸钠、来氟米特和阿司匹林混合在一起，研磨成粉末并且过35目筛子，得到第一混合物，备用；
步骤二，将谷维素、维生素E、赖氨酸、咖啡因、葫芦素和土霉素放入生理盐水中，搅拌机在常温下以150rpm的转速搅拌20分钟，即可得到第一混合溶液；
步骤三，将第一混合物加入第一混合溶液中并且进行搅拌，边搅拌边加入石斛液和甘油，完全加入完毕后搅拌机在36摄氏度下以300rpm的转速搅拌40分钟，得到第二混合溶液，再将第二混合溶液进行浓缩和干燥，得到干浸膏，将干浸膏粉碎成粉末并且与辅料充分混合均匀，制成片剂、丸剂或者胶囊。
实施例3
一种用于治疗风湿病的药物，由以下原料按照重量份组成：辅料4份、石斛液6份、水杨酸钠1.8份、来氟米特1.3份、谷维素3.5份、维生素E0.5份、赖氨酸3.6份、咖啡因3份、葫芦素7份、阿司匹林2份、土霉素1.5份、甘油5.2份和生理盐水16份。石斛汁液采用石斛煎煮4次，每次1小时，合并4次煎煮后的液体并且去除残渣得到。辅料采用明胶。
所述用于治疗风湿病的药物的制备方法，具体步骤如下：
步骤一，将水杨酸钠、来氟米特和阿司匹林混合在一起，研磨成粉末并且过30目筛子，得到第一混合物，备用；
步骤二，将谷维素、维生素E、赖氨酸、咖啡因、葫芦素和土霉素放入生理盐水中，搅拌机在常温下以160rpm的转速搅拌22分钟，即可得到第一混合溶液；
步骤三，将第一混合物加入第一混合溶液中并且进行搅拌，边搅拌边加入石斛液和甘油，完全加入完毕后搅拌机在45摄氏度下以300rpm的转速搅拌50分钟，得到第二混合溶液，再将第二混合溶液进行浓缩和干燥，得到干浸膏，将干浸膏粉碎成粉末并且与明胶充分混合均匀，制成片剂、丸剂或者胶囊
实施例4
一种用于治疗风湿病的药物，由以下原料按照重量份组成：辅料5份、石斛液7份、水杨酸钠2份、来氟米特1.5份、谷维素4份、维生素E1份、赖氨酸4份、咖啡因4份、葫芦素9份、阿司匹林2.5份、土霉素2份、甘油6份和生理盐水18份。石斛汁液采用石斛煎煮3次，每次2小时，合并3次煎煮后的液体并且去除残渣得到。辅料采用淀粉、糊精、聚维酮、硬脂酸钠、植物油、明胶、羧甲基淀粉钠、液体石蜡和虫胶的混合物。
所述用于治疗风湿病的药物的制备方法，具体步骤如下：
步骤一，将水杨酸钠、来氟米特和阿司匹林混合在一起，研磨成粉末并且过50目筛子，得到第一混合物，备用；
步骤二，将谷维素、维生素E、赖氨酸、咖啡因、葫芦素和土霉素放入生理盐水中，搅拌机在常温下以180rpm的转速搅拌20分钟，即可得到第一混合溶液；
步骤三，将第一混合物加入第一混合溶液中并且进行搅拌，边搅拌边加入石斛液和甘油，完全加入完毕后搅拌机在45摄氏度下以360rpm的转速搅拌40分钟，得到第二混合溶液，再将第二混合溶液进行浓缩和干燥，得到干浸膏，将干浸膏粉碎成粉末并且与辅料充分混合均匀，制成片剂、丸剂或者胶囊。
对比例
除不含有石斛液，对比例1的其余组分和制备方法均与实施例2相同。除不含有葫芦素，对比例2的其余组分和制备方法均与实施例3相同。
选择相同状况的风湿病人700个，随机平均分为1-7组，每组100人，各组的年龄和性别上基本相同，将实施例1-4的产品给1-4组的患者服用，将对比例1和对比例2的产品给5-6组患者服用，将现有产品给7组的患者服用，每天2次每次2g并且采用温开水送服，两周为一个疗程，持续三个疗程，治疗结果见表1。
疗效判定标准：痊愈：风湿病症状完全消失，两年内不再复发。好转：风湿病症状减轻一半以上。无效：风湿病症状没有减轻甚至加重。
表1
从表1可以看出，实施例1-4产品的治愈率和有效率均优于对比例1-2的产品和现有产品，治疗效果好。实施例1-4的产品在使用过程中，患者没有任何不适，患者在服药期间忌辛辣等刺激性食物、忌酒和海鲜。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (4)
1.一种用于治疗风湿病的药物，其特征在于，由以下原料按照重量份组成：辅料2-5份、石斛液3-7份、水杨酸钠1-2份、来氟米特0.2-1.5份、谷维素2-4份、维生素E0.2-1份、赖氨酸2-4份、咖啡因1-4份、葫芦素4-9份、阿司匹林0.5-2.5份、土霉素0.4-2份、甘油3-6份和生理盐水10-18份。
2.根据权利要求1所述的用于治疗风湿病的药物，其特征在于，所述石斛汁液采用石斛煎煮2-4次，每次1-2小时，合并煎煮后的液体并且去除残渣得到。
3.根据权利要求1或2所述的用于治疗风湿病的药物，其特征在于，所述辅料采用淀粉、糊精、聚维酮、硬脂酸钠、植物油、明胶、羧甲基淀粉钠、液体石蜡和虫胶的一种或者几种的混合物。
4.一种如权利要求1-3任一所述的用于治疗风湿病的药物的制备方法，其特征在于，具体步骤如下：
步骤一，将水杨酸钠、来氟米特和阿司匹林混合在一起，研磨成粉末并且过30-50目筛子，得到第一混合物，备用；
步骤二，将谷维素、维生素E、赖氨酸、咖啡因、葫芦素和土霉素放入生理盐水中，搅拌机在常温下以120-180rpm的转速搅拌15-25分钟，即可得到第一混合溶液；
步骤三，将第一混合物加入第一混合溶液中并且进行搅拌，边搅拌边加入石斛液和甘油，完全加入完毕后搅拌机在30-45摄氏度下以240-360rpm的转速搅拌30-50分钟，得到第二混合溶液，再将第二混合溶液进行浓缩和干燥，得到干浸膏，将干浸膏粉碎成粉末并且与辅料充分混合均匀，制成片剂、丸剂或者胶囊。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611107181.3A CN106377677A (zh) | 2016-12-06 | 2016-12-06 | 一种用于治疗风湿病的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611107181.3A CN106377677A (zh) | 2016-12-06 | 2016-12-06 | 一种用于治疗风湿病的药物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106377677A true CN106377677A (zh) | 2017-02-08 |
Family
ID=57959428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611107181.3A Pending CN106377677A (zh) | 2016-12-06 | 2016-12-06 | 一种用于治疗风湿病的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106377677A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131557A (zh) * | 1995-11-02 | 1996-09-25 | 谢志庆 | 一种治疗类风湿病的中药丸剂 |
| CN101647801A (zh) * | 2009-08-11 | 2010-02-17 | 华东师范大学 | 一种四环三萜化合物在制备抑制血管新生药物中的应用 |
| CN102188621A (zh) * | 2011-05-12 | 2011-09-21 | 中国药科大学 | 玫瑰石斛总生物碱制备治疗急慢性炎症、急慢性关节炎或类风湿性关节炎疾病药物的应用 |
| CN103285240A (zh) * | 2013-03-07 | 2013-09-11 | 上海仙草堂保健食品有限公司 | 一种石斛西洋参含片及其制备方法 |
-
2016
- 2016-12-06 CN CN201611107181.3A patent/CN106377677A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131557A (zh) * | 1995-11-02 | 1996-09-25 | 谢志庆 | 一种治疗类风湿病的中药丸剂 |
| CN101647801A (zh) * | 2009-08-11 | 2010-02-17 | 华东师范大学 | 一种四环三萜化合物在制备抑制血管新生药物中的应用 |
| CN102188621A (zh) * | 2011-05-12 | 2011-09-21 | 中国药科大学 | 玫瑰石斛总生物碱制备治疗急慢性炎症、急慢性关节炎或类风湿性关节炎疾病药物的应用 |
| CN103285240A (zh) * | 2013-03-07 | 2013-09-11 | 上海仙草堂保健食品有限公司 | 一种石斛西洋参含片及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 胡晋红 主编: "《新编常用药物手册》", 31 March 2009, 金盾出版社 * |
| 茅伟安 主编: "《皮肤病用药速查手册》", 30 April 2014, 金盾出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102973610A (zh) | 利用美洲大蠊提取浸膏制备肺结核辅助药的方法 | |
| CN103055260A (zh) | 一种治疗溃疡性结肠炎的中药组合物及其制备方法 | |
| CN106377677A (zh) | 一种用于治疗风湿病的药物及其制备方法 | |
| CN103784905A (zh) | 一种治疗猪水肿的中药散剂及其制备方法 | |
| CN101837022A (zh) | 一种治疗胃炎和消化性溃疡的美洲大蠊药物组合物及其制备方法 | |
| CN106511779A (zh) | 一种用于治疗风湿病的西药组合及其制备方法 | |
| CN103623291B (zh) | 一种治疗癌症的中药组合物及其制备方法 | |
| CN102579568B (zh) | 一种用于治疗各种出血症的纯中药药物组合物及其制备方法 | |
| CN102552743A (zh) | 一种用于治疗糖尿病的药物组合物及其制备方法 | |
| CN106620283A (zh) | 一种用于治疗类风湿性关节炎的药物及其制备方法 | |
| CN102266456B (zh) | 一种治疗骨伤病的药物及其制备 | |
| CN101744979A (zh) | 一种治疗牙痛的药物及其制备方法 | |
| CN101194943B (zh) | 一种治疗肛裂的熏洗药物 | |
| CN104398868B (zh) | 一种治疗痔疮的复方中药 | |
| CN106138968A (zh) | 肠胃修复及保护肠胃黏膜的药食同源组合物及其制备方法 | |
| CN109498553A (zh) | 一种痔疮膏配方及其制备方法 | |
| CN101954046A (zh) | 一种治疗乳腺增生的药物 | |
| CN105943601A (zh) | 一种治疗痔疮的中药配方及其制备方法 | |
| CN101716191A (zh) | 一种治疗褥疮的外敷中药组合物 | |
| CN101708284B (zh) | 一种治疗痔疮的药物 | |
| CN107115424A (zh) | 改变酸性体质保钙及清热解毒的中药组合物及制备方法 | |
| CN105616500A (zh) | 一种治疗绦虫病的药物组合物及其制备方法 | |
| CN106729409A (zh) | 一种用于儿童腹股沟疝护理的中药组合物 | |
| CN1679908A (zh) | 一种治疗肿瘤的中药及其制备方法 | |
| CN104434998A (zh) | 一种治疗乳腺增生的中药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170208 |